Biopharmx Corp (NYSEAMERICAN:BPMX) shares were down 8.3% during mid-day trading on Friday . The stock traded as low as $0.11 and last traded at $0.11. Approximately 2,834,352 shares traded hands during mid-day trading, an increase of 78% from the average daily volume of 1,589,471 shares. The stock had previously closed at $0.12.

Several research analysts have issued reports on BPMX shares. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Biopharmx in a report on Wednesday, September 13th. Maxim Group reissued a “buy” rating and issued a $1.50 price objective (down from $3.00) on shares of Biopharmx in a research note on Wednesday, September 13th.

The firm has a market cap of $14.47, a P/E ratio of -0.42 and a beta of 1.32.

In related news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen Morlock bought 330,000 shares of the firm’s stock in a transaction on Friday, November 24th. The stock was purchased at an average cost of $0.15 per share, with a total value of $49,500.00. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY WARNING: “Biopharmx (BPMX) Shares Down 8.3%” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/12/31/biopharmx-bpmx-shares-down-8-3.html.

Biopharmx Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.